Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood pressure drug study in septic shock halted early

NCT ID NCT06426407

Knowledge-focused Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study aimed to understand why some septic shock patients respond better to the drug vasopressin. Researchers planned to compare blood markers, heart ultrasound images, and tissue oxygen levels between responders and non-responders. However, the study was terminated after enrolling only 2 participants, so no meaningful conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vasopressin
What this could lead to
If successful, this could help doctors identify which septic shock patients benefit most from vasopressin, potentially leading to more personalized treatment.
What could go wrong
The study was terminated early with only 2 participants, so results are very limited and may not be reliable or generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2 people

The number who actually took part.

Started

Oct 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with septic shock are eligible for this study. Patients ordered vasopressin as an adjunct to norepinephrine as part of routine care comprise the primary cohort of interest. An active control cohort of patients who are only receiving norepinephrine will also be enrolled.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years old) * Septic shock (as defined by Sepsis-3) * Receiving norepinephrine * Admitted to a medical, surgical, NeuroSciences, or mixed intensive care unit * Central venous catheter in place * Ordered fixed-dose vasopressin as an adjunct to norepinephrine by the primary care team (unless in active control cohort) Exclusion Criteria: * Vasopressin ordered for an indication other than septic shock * Vasopressin initiated at another institution * Receiving a primary vasopressor other than norepinephrine (eg, phenylephrine) * Positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the preceding 28 days * Blood hemoglobin concentration \<7 g/dL * Primary treatment team determines that vasopressin initiation is emergent * Patient or their legal authorized representative opts to not participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Shock, septic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Shock, septic

Contacts and locations

Locations

  • Cleveland Clinic Main Campus

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.